// App-Quantinova.ai

77 : Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Researchers

Presenter

  • Robert Zeiser

Principal Investigators

  • Nicola Polverelli

  • Ron Ram

  • Shahrukh K. Hashmi

  • Ronjon Chakraverty

  • Mary E. D. Flowers

  • Fitzroy Dawkins

  • Norbert Hollaender

  • Maanasa Gowda

  • Tommaso Stefanelli

  • Stephanie J. Lee

  • Takanori Teshima

  • Franco Locatelli

Medical Centers

  • Medical Faculty University of Freiburg, Freiburg Im Breisgau, GA, Germany

  • Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Sciences, ASST-Spedali Civili, University of Brescia, Brescia, Italy

  • Tel Aviv Sourasky Medical Center and Sakler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

  • Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

  • UCL Cancer institute and Institute of Immunity and Transplantation, London, United Kingdom

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Incyte Corporation, Wilmington, DE

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Department of Hematology,Hokkaido University Faculty of Medicine,Sapporo,Japan

Locations

  • Germany

  • Israel

  • Saudi Arabia

  • United Kingdom

  • United States

  • Switzerland

  • Japan

  • Italy

Companies

  • Incyte Corporation

  • Novartis AG

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Controlled

Phase

  • III

Study Id's

  • NCT03112603

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved